Valentia Biopharma Overview
- Founded
- 2006
- Status
- Out of Business
- Latest Deal Type
- Out of Business
Valentia Biopharma General Information
Description
Provider of a novel drug discovery platform designed to generate a broad pipeline of first-in-class drugs. The company's novel drug discovery platform analyzes thousands of compounds and have a capacity to reproduce the process of massive molecule testing in vivo using Drosophila individuals enabling the development of additional drugs to treat human diseases.
Contact Information
Website
www.valentiabiopharma.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Primary Office
- Parc Científic de la Universitat de València
- C/Catedrático José Beltrán, 2
- 46980 Valencia
- Spain
+34 963 00 00 00
Valentia Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Feb-2016 | Completed | Out of Business | |||
| 1. Early Stage VC | 26-Jun-2008 | Completed | Startup |
Valentia Biopharma Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Rebeca Lucas | Co-Founder & Chief Executive Officer | ||
| Manuel Perez-Alonso Ph.D | Co-Founder & Scientific Director |